The strains. The CFU count. The protocol. The results. The follow-up data.
I wrote a paper and submitted it for publication.
I wanted other dermatologists to see this. I wanted women to know there was another option.
The paper was accepted by a dermatology journal and published.
But the response was... underwhelming.
A few colleagues reached out privately. Supportive, curious. But most of the industry ignored it.
I tried to get media coverage. I thought this was exactly the kind of story health publications would want to run — a new approach to a problem millions of women struggle with.
But no major outlet would pick it up.
When I pushed for answers, the feedback I got was always some version of: "It's not aligned with our advertising partners" or "We don't cover unproven alternatives."
Unproven. Despite the data I'd just published.
I realised something. The skincare industry is built on selling products that manage symptoms. Products you have to keep buying forever.
A solution that actually fixes the root cause? That doesn't fit the business model.
I felt like my research was going to waste. Like I'd found an answer and nobody wanted to hear it.
I started to accept that maybe this would just help the patients I could reach directly. That would have to be enough.
Then Skinfora Reached Out
A few months after my paper was published, I got an email from a small company called Skinfora.